Enterprise Associates 16 New Buys 554,250 Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) Stock

Marker Therapeutics, Inc. (NASDAQ:MRKR) major shareholder Enterprise Associates 16 New bought 554,250 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was purchased at an average cost of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the transaction, the insider now owns 1,625,678 shares in the company, valued at $5,202,169.60. This represents a 51.73 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Marker Therapeutics Stock Down 10.0 %

Marker Therapeutics stock opened at $3.42 on Tuesday. Marker Therapeutics, Inc. has a twelve month low of $2.44 and a twelve month high of $6.16. The stock’s fifty day simple moving average is $3.72 and its 200-day simple moving average is $3.84.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Marker Therapeutics stock. Invst LLC acquired a new stake in Marker Therapeutics, Inc. (NASDAQ:MRKR) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 20,000 shares of the company’s stock, valued at approximately $56,000. Invst LLC owned 0.22% of Marker Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 22.39% of the company’s stock.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH lifted their price objective on shares of Marker Therapeutics from $11.00 to $19.00 and gave the company a “buy” rating in a report on Monday, October 21st.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.